Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study

• Published in: PloS one 2014-02, Vol.9 (2), p.e89516-e89516
• Main Authors: Ihara, Masafumi, Nishino, Madoka, Taguchi, Akihiko, Yamamoto, Yumi, Hattori, Yorito, Saito, Satoshi, Takahashi, Yukako, Tsuji, Masahiro, Kasahara, Yukiko, Takata, Yu, Okada, Masahiro
• Format: Article
• Language: English
• Subjects: Aged; Alzheimer's disease; Apoptosis; Biomedical research; Brain research; Care and treatment; Cholinesterase Inhibitors - therapeutic use; Cognitive ability; Combinatorial analysis; Dementia; Dementia - drug therapy; Dementia disorders; Diabetes; Donepezil; Drug Therapy, Combination; Epidemiology; Female; Follow-Up Studies; Geriatrics; Hospitals; Humans; Hypertension; Identification methods; Indans - therapeutic use; Male; Medical records; Medical research; Medicine; Multivariate analysis; Neurodegeneration; Neuroprotective Agents - therapeutic use; Neuropsychological Tests; Neurosurgery; Older people; Patients; Phosphodiesterase; Piperidines - therapeutic use; Prognosis; Retrospective Studies; Rodents; Stroke; Tetrazoles - therapeutic use; Therapy; Tissue engineering; Vascular diseases
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0089516

Combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia may offer a promising strategy for treatment of dementia, which often has a multifactorial basis in the elderly. We investigated whether the phosphodiesterase III inhibitor cilostazol, which is often used in the prevention of stroke and peripheral artery disease, may delay cognitive decline in the elderly receiving donepezil. Medical records were retrospectively surveyed to identify patients who had received donepezil for more than one year and had undergone Mini-Mental State Examination (MMSE) at least at two time points. Those with an initial MMSE score of less than 27 points were subjected to analysis (n = 156), with a cut-point of 21/22 applied to assign them to mild (n = 70) and moderate/severe (n = 86) dementia. The change of total MMSE score per year was compared between patients who had received donepezil and those given both donepezil and cilostazol. In patients with mild dementia who had received donepezil and cilostazol (n = 34; 77.2±6.8 years old), the annual change in MMSE score was -0.5±1.6 during an observational period of 28.6±11.7 months, with those receiving donepezil only (n = 36; 78.4±6.5 years old) scoring less (-2.2±4.1) during 30.4±12.8 months with a statistical intergroup difference (p = 0.022). Multivariate analysis showed that absence of cilostazol treatment was the only significant predictor of MMSE decline. A positive effect of cilostazol was found in three subscale scores of MMSE, orientation for time or place and delayed recall. By clear contrast, in patients with moderate/severe dementia, there were no intergroup differences in decrease of total or subscale MMSE scores between the two groups. These results suggest potential for cilostazol treatment in the suppression of cognitive decline in patients receiving donepezil with mild dementia but not in those with moderate/severe dementia.